TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233786

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
Study: NCT06589310

Intervention type: DEVICE
Intervention: Exact Sciences Multicancer Early Detection (MCED) Test
Description: Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.
Study: NCT05045820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needling acupuncture
Description: Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needling acupuncture
Description: Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
Study: NCT04777981

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBDRA60 supplement
Description: CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06021327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 3 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact the tip of the T4 transverse process , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. Adequacy of the block will be confirmed by ultrasonographic visualization of fluid spread (seen as a lifting of the erector spina muscles in both block) and after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block
Description: Under aseptic precautions, the ultrasound transducer will be placed on the patient's back in a longitudinal paramedian orientation approximately 1 cm from the midline. A short-bevel, 80 mm 22-gauge insulated nerve block needle will be inserted using an in-plane approach to contact T4 lamina of the vertebra , After negative aspiration of blood, a total of 20 mL of 0.25% bupivacaine will be injected through the needle. And after 15 min, documenting the sensory blockade will be done by using a piece of ice or cold object. If the desired sensory level fails to be achieved (T4 - T8), patients will be excluded from the study.
Study: NCT04017767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induced Acute Intermittent Hypoxia (AIH)
Description: AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Acute Intermittent Hypoxia (AIH)
Description: AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIH mask
Description: Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIH mask
Description: Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
Study: NCT05150431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
Study: NCT05045820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
Study: NCT06679621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Description: This telehealth intervention will be made using human centered design methods
Study: NCT06681428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Placental-based Allografts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Placental-based Allografts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Placental-based Allografts
Study: NCT06695130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV (recombinant influenza vaccine)
Description: Influenza, inactivated, split virus or surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV (recombinant influenza vaccine)
Description: Influenza, inactivated, split virus or surface antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rC19 (dose 1)
Description: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rC19 (dose 1)
Description: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV + rC19 (dose 1)
Description: RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV + rC19 (dose 2)
Description: RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV + rC19 (dose 3)
Description: RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV + rC19 (dose 4)
Description: RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline
Study: NCT06619756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonomotor Treatment (PMT)
Description: Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological Components Analysis (PCA)
Description: Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
Study: NCT06688799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study: NCT06716658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK1 Inhibitor
Description: Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
Study: NCT06715150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromcyin
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
Study: NCT06718335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.
Study: NCT06723184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The training
Description: Behavioral: Antenatal Education Education Hours: The training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be in a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Grandmothers in both the control and intervention groups will be asked to fill out the Introductory Information Form, Pharis Self-Confidence Scale, State-Trait Anxiety Scale and Knowledge Measurement Questionnaire for Grandchild Care measurement tools. The data of the intervention group will be filled in before and after the training. The data of the control group will be filled in parallel with the intervention group. At the end of the study, the same training will be applied to the control group.~Group to receive training: Grandmothers who are expecting a grandchild and have a grandchild will be included in the training.
Study: NCT06728774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD)
Description: 8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-focused Supportive Contact
Description: 8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.
Study: NCT06728865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The treatment regimen is Furmonertinib combined with Bevacizumab.
Description: The treatment regimen is Furmonertinib combined with Bevacizumab.
Study: NCT06728020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Conventional rehabilitation (Group A)
Description: The conventional group will undergo standard rehabilitation treatment according to the rehabilitation plan developed by the rehabilitation team. This group will undergo 3 hours of rehabilitation per day and will carry out face-to-face rehabilitation following an impairment-based approach aimed at the treatment of motor-cognitive functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROOMMATE 1st
Description: In addition to Group A, this group will have the bedside multimedia monitor apparatus to access informative, rehabilitation, and entertainment content. Additionally, this group will have a digital and innovation coach to receive support in using the technology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROOMMATE 2nd
Description: Once the first RCT of the cmRCT is completed, a pilot RCT will be initiated, randomizing 60 cases between Group A and this group. In addition to conventional treatment, this group will have a version of the ROOMMATE system integrated with inertial sensors worn on the hands and fingers to guide the serious games on the platform.
Study: NCT06727630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day
Study: NCT06729242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT session
Description: The HIIT exercise will consist of strength exercises with elastic bands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT session
Description: The HIIT exercise will consist of strength exercises with elastic bands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT session
Description: The HIIT exercise will consist of strength exercises with elastic bands.
Study: NCT06729229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement/Vitamins
Description: Experimental - Control lunch (no fish) and omega 3 supplement
Study: NCT05759637

Intervention type: DIAGNOSTIC_TEST
Intervention: 1mg DST
Description: measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm

Intervention type: DIAGNOSTIC_TEST
Intervention: 1mg DST
Description: measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
Study: NCT05225948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
Study: NCT05343325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
Study: NCT04925557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mayzent
Description: PET imaging to evaluate the effects of Mayzent on the microglia of the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrevus
Description: PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
Study: NCT06163001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercises
Description: 4 weeks of preoperative supervised aerobic and resistance exercises

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplementation
Description: 4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation
Description: 4 weeks of preoperative Standard medical therapy which will consist of dietary advice and supplementation
Study: NCT05934474

Intervention type: BIOLOGICAL
Intervention: Peripheral venipuncture blood sampling, as part of standard care procedures
Description: Collection of 36 mL of blood

Intervention type: OTHER
Intervention: Interview with a psychiatrist
Description: Research project data collection
Study: NCT06422728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Anxiety Disorders
Description: The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Client-centered Supportive Therapy
Description: Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
Study: NCT05604365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FearLess Intervention
Description: 8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.